logologo

Popular Boards

2 Mentions
Rebecca L. Siegel, Lindsey A. Torre, Isabelle Soerjomataram | Gut | (2019)
Primary Link Pubmed DOI Openalex Full text (OA)

Key Takeaways

Sample Definition And Size

The study analyzed long-term, population-based colorectal cancer (CRC) incidence data from 43 countries across six continents, comparing adults aged under 50 years (“young adults”) versus those aged 50 years and older. During 2008–2012, age-standardized CRC incidence rates in adults under 50 ranged from 3.5 per 100,000 (95% CI 3.2–3.9) in India (Chennai) to 12.9 (95% CI 12.6–13.3) in Korea. Trends were assessed across 36 countries: incidence in adults under 50 was stable in 14 countries, declined in Austria, Italy, and Lithuania, and increased in 19 countries, including nine high-income countries where older adult incidence was stable or declining (Australia, Canada, Denmark, Germany, New Zealand, Slovenia, Sweden, UK, USA) ([coloncancerfoundation.org](https://coloncancerfoundation.org/wp-content/uploads/2019/10/Siegel2019_Global-patterns-EO-CRC_Gut.pdf?utm_source=openai)).

Study Type

Observational ecological study using registry-based incidence data; specifically, a global trend analysis of CRC incidence by age group using data from Cancer Incidence in Five Continents and supplemental sources ([coloncancerfoundation.org](https://coloncancerfoundation.org/wp-content/uploads/2019/10/Siegel2019_Global-patterns-EO-CRC_Gut.pdf?utm_source=openai)).

Conflicts Of Interest

No conflicts of interest are reported in the accessible summary; the news release and abstract do not mention any declared conflicts ([eurekalert.org](https://www.eurekalert.org/news-releases/860478?utm_source=openai)).

Results Summary

Key findings include: during 2008–2012, CRC incidence in adults under 50 varied globally from 3.5 to 12.9 per 100,000 (95% CIs provided). Among 36 countries, incidence in young adults was stable in 14, declined in three (Austria, Italy, Lithuania), and increased in 19 countries. In nine high-income countries, increases occurred exclusively in young adults while older adult incidence was stable or declining. In some countries (e.g., Norway), the average annual percent change (AAPC) in young adults was 1.9% (95% CI 1.4–2.5) versus 0.5% (95% CI 0.3–0.7) in older adults. The steepest increases were in Korea (AAPC 4.2%, 95% CI 3.4–5.0) and New Zealand (AAPC 4.0%, 95% CI 2.1–6.0) ([coloncancerfoundation.org](https://coloncancerfoundation.org/wp-content/uploads/2019/10/Siegel2019_Global-patterns-EO-CRC_Gut.pdf?utm_source=openai)).

Abstract

CRC incidence increased exclusively in young adults in nine high-income countries spanning three continents, potentially signalling changes in early-life exposures that influence large bowel carcinogenesis.

Referenced In

William Fan
2 months ago
Health, Fitness, and Nutrition

A great read on advances in colorectal cancer detection. I mentioned in a comment that the global rate of CRC is dramatically increased for young adults for seemingly unknown reasons. It's important to get screened earlier now and for the technology to become more accessible.

Read Full Post
Mercedes C.
2 months ago
AI Papers and Discussion

Colorectal Cancer (CRC) is the 3rd most common cancer worldwide 🌍 , accounting for approximately 10% of all cancer cases.

According to world health organisation (WHO) - in 2022, an estimated 1.9 million new cases of colorectal cancer and more than 900 000 deaths 💀 occurred worldwide.

With the wave of AI-powered innovations transforming how we predict patient outcomes, stratify risk, and personalise treatment: Here are THREE landmark studies from 2025-2026, targeting colorectal cancer.

🔬 SurvFinder: Deep Learning Discovers Novel Prognostic Biomarkers

The Innovation: Researchers built a multi-view deep learning system that analyzes routine H&E slides from multiple angles to identify something pathologists rarely assess systematically: tertiary lymphoid structures (TLSs). These organised immune cell clusters form in response to tumours, and their location and maturity strongly predict outcomes.

The Achievement:

  • 6,950 slides from 1,604 patients across 4 independent cohorts

  • AUROC of 0.827 for predicting recurrence risk

  • High-risk patients showed 8.23× higher hazard for relapse than low-risk

Why It Matters: SurvFinder discovered a clinically actionable biomarker hidden in ordinary microscope slides of tumour tissue. In a disease where 20% relapse post-surgery, this system allows for better treatment plans.

🩸 ColoLDB: Making Precision Medicine Accessible

The Innovation: This is a machine learning model that uses only standard laboratory parameters — complete blood counts, liver function tests, inflammatory markers, and basic metabolic panels — to predict CRC risk and outcomes.

The Achievement:

  • Uses XGBoost and ensemble methods for robust predictions

  • Requires no specialized equipment beyond existing lab infrastructure, which enables population-level screening in resource-limited settings

  • Demonstrated comparable performance to more complex multi-modal systems in specific prediction tasks

Why It Matters: While digital pathology AI grabs headlines, ColoLDB addresses global health equity. By leveraging existing lab infrastructure, it brings AI-powered risk prediction to low-resource settings where CRC mortality remains highest.

🧬 HIBRID: When Two Tests Become One Smart Prediction

The Innovation: First system to combine AI analysis of microscope slides with circulating tumour DNA (ctDNA) blood tests — fusing analysis on how the tumour looks like and whether tumour DNA remains in the body.

The Achievement:

  • Tested on 1,023 stage II patients and Identified four distinct risk strata enabling nuanced treatment decisions

  • Found patients with scary-looking tumours but clean blood tests still face 18% recurrence risk

  • Found patients with benign-looking tumours but positive blood tests face 31% recurrence risk

Why It Matters: HIBRID establishes multi-modal AI as clinically viable, not experimental. It transforms binary treatment decisions into probabilistic, personalised medicine — sparing low-risk patients chemotherapy toxicity while ensuring high-risk patients receive intervention.

Read Full Post
1
Mar 26, 2026 3:32 AM

Such an important topic, there's been a huge increase in colorectal cancer rates among young adults globally, even though the usual key indicators have been declining. Something pernicious is happening and it really scares me. The second paper is very interesting, it's fascinating to me to see even in 2026 how a simple XGBoost model can still provide massive boosts in detection. It just goes to show that really data is the key and traditional ML models still have a huge role to play, even as part of a larger ensemble AI protocol.